Eloxx Pharmaceuticals, Inc. ELOX PHARMA
Company Overview
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Why Investors Should Care
Generates a return on equity of 50.3%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 54.1%.
Trades at a P/E of 4.6, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.25.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +46.87% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -7.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)49.23 · Neutral
P/E of 4.59 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 50.3%.
- Healthy ROCE of 54.1%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELOX Eloxx Pharmaceuticals, Inc. PHARMA | 16.17 | 4.59 | $55.57M | 0.00% | 54.07% | 50.35% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2011 | Mar 2012 | Sep 2012 | Dec 2012 | Mar 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200.00K | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.46M | -1.11M | -1.25M | -1.30M | -1.04M | -1.75M | -1.59M | -2.13M | -5.19M | -10.75M | -1.22M | -1.15M | -3.76M | -4.89M | -2.21M | -1.51M | -2.63M | -3.18M | -4.00M | - | -8.55M | -13.54M | -11.36M | -11.98M | -14.31M | -12.78M | -13.77M | -7.59M | -6.30M | -8.41M | -35.73M | -10.24M | -10.95M | -10.30M | -7.14M | -5.48M | -4.14M | -3.64M | -1.22M | -3.79M |
| Net Income | -1.53M | -1.06M | -2.09M | -1.27M | -836.58K | -1.78M | -1.62M | -2.15M | -5.18M | -10.75M | -1.23M | -180.74K | -3.86M | -3.08M | -933.58K | -789.83K | -2.68M | -3.88M | -4.04M | -10.60M | -8.59M | -13.41M | -11.16M | -11.92M | -14.45M | -12.88M | -13.95M | -7.89M | -6.62M | -8.69M | -36.06M | -9.88M | -11.62M | -10.62M | -7.51M | -6.23M | -4.34M | -3.59M | -1.71M | -3.75M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.54 | -0.11 | -5.36 | -4.90 | -3.47 | -2.88 | -1.96 | -1.31 | -0.45 | -0.08 |
| R&D Expense | 751.52K | 540.79K | 513.43K | 591.08K | 492.85K | 810.94K | 730.82K | 966.34K | 2.12M | 1.37M | 235.25K | 601.58K | 594.50K | 576.44K | 280.24K | 207.38K | 2.35M | 2.60M | 3.28M | 8.40M | 4.39M | 4.15M | 5.42M | 6.02M | 7.34M | 6.80M | 4.77M | 3.70M | 3.40M | 4.07M | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 1999 | Jun 2000 | Jun 2001 | Jun 2002 | Jun 2003 | Jun 2004 | Jun 2005 | Jun 2006 | Jun 2007 | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Dec 2015 | Jun 2016 | Dec 2016 | Jun 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.82K | 182.23K | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 6.36M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.42M | 17.29M | 8.83M | 6.44M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | -7.92M | -5.41M | -4.65M | -9.15M | -18.08M | -6.28M | -11.19M | -9.84M | -4.59M | -20.39M | -47.56M | -50.55M | -33.45M | - | -34.42M | -17.29M | -2.47M | -6.44M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.42M | -15.09M | -1.83M | -4.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.95M | 1.15M | 1.14M | 1.05M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -36.06M | -17.05M | -3.14M | -6.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.17M | -3.35M | -2.03M | -3.02M | -2.78M | -3.73M | -2.98M | -3.31M | -3.25M | -4.60M | -5.73M | -13.38M | -7.27M | -5.07M | -6.12M | -9.23M | -18.06M | -6.41M | -8.27M | -9.85M | -5.80M | -21.21M | -47.19M | -50.87M | -34.58M | - | -36.06M | -17.05M | -3.14M | -6.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -183.15 | -72.93 | -9.24 | -5.39 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | 3.72M | 2.57M | 2.09M | 3.34M | 4.57M | 5.84M | 2.18M | 8.99M | 733.66K | 16.40M | 20.49M | 26.35M | 14.59M | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 1998 | Jun 1999 | Jun 2000 | Jun 2001 | Jun 2002 | Jun 2003 | Jun 2004 | Jun 2005 | Jun 2006 | Jun 2007 | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Dec 2014 | Jun 2015 | Dec 2015 | Jun 2016 | Dec 2016 | Jun 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.95M | 7.10M | 33.33M | - | 19.55M | - | 9.23M | 3.13M | 5.85M | 24.78M | 50.72M | 58.95M | 26.48M | 45.14M | 21.12M | 1.71M | 2.98M | 5.27M |
| Total Equity | 0 | 912.17K | 1.52M | -206.71K | 4.79M | 2.86M | 4.73M | 5.59M | 2.95M | 2.69M | 9.84M | 5.67M | 7.98M | 4.52M | 3.45M | 3.79M | 27.49M | 2.77M | 12.22M | 643.00K | 4.56M | 610.00K | 871.21K | 21.36M | 42.91M | 36.21M | 10.23M | 22.38M | -10.66M | -22.60M | -24.34M | -11.91M |
| Cash & Equivalents | 0 | - | - | - | - | - | - | - | - | - | - | - | 8.03M | 3.61M | 2.00M | 1.60M | 6.11M | 1.74M | 3.33M | 1.37M | 810.81K | 2.21M | 33.20K | 24.05M | 48.61M | 22.49M | 24.67M | 42.27M | 19.21M | 1.13M | 111.00K | 4.79M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.50M | 6.38M | 12.00M | 8.56M | 1.61M | 0 | 0 |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.50M | 3.31M | 5.84M | - | 7.32M | - | 4.67M | - | 4.97M | - | 7.81M | 22.73M | 16.25M | 22.75M | 31.78M | 24.31M | 27.31M | 17.18M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.16M | 3.21M | 1.83M | - | 778.52K | - | 368.99K | 2.52M | 2.77M | 3.42M | 7.81M | 11.81M | 9.84M | 9.96M | 23.09M | 22.70M | 27.31M | 17.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Dec 2015 | Jun 2016 | Dec 2016 | Jun 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.39M | -4.39M | -3.90M | -4.87M | - | -5.74M | - | -8.84M | - | -15.94M | -31.37M | -39.39M | -28.17M | -35.00M | -31.84M | -14.34M | -4.71M | -6.33M |
| Investing Cash Flow | -686.42K | -450.50K | -529.04K | 646.94K | - | 1.49M | - | -36.00K | - | -114.00K | -317.00K | -33.52M | 33.79M | 2.06M | -66.00K | 309.00K | 38.00K | 1.00K |
| Financing Cash Flow | 1.66M | 3.23M | 4.03M | 8.73M | - | 3.88M | - | 9.74M | - | 37.95M | 56.18M | 46.80M | -3.44M | 50.79M | 8.81M | -4.08M | 3.44M | 11.00M |
| Capital Expenditure | -2.03K | -4.46K | -1.28K | -3.19K | -122.64K | -10.00K | -0 | -36.00K | -2.50K | -237.00K | -235.00K | -40.00K | - | -89.00K | -66.00K | - | - | - |
| Free Cash Flow | -5.39M | -4.39M | -3.90M | -4.87M | - | -5.75M | - | -8.88M | - | -16.17M | -31.60M | -39.43M | - | -35.09M | -31.91M | - | - | - |
| Dividends Paid | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 1999 | Jun 2000 | Jun 2001 | Jun 2002 | Jun 2003 | Jun 2004 | Jun 2005 | Jun 2006 | Jun 2007 | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Dec 2015 | Jun 2016 | Dec 2016 | Jun 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -59,476.9% | -5,019.9% | - | - | - | - | - | - | - | - | - | - | - | - | -38.8% | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -78,303.4% | -5,062.4% | - | - | - | - | - | - | - | - | - | - | - | - | -49.4% | - |
| ROE % | -128.2% | -220.4% | 983.9% | -63.1% | -97.3% | -78.8% | -53.3% | -112.3% | -120.9% | -46.8% | -101.0% | -167.7% | -160.9% | -146.7% | -161.7% | -33.6% | -147.8% | -996.3% | -181.3% | -1,614.3% | -665.3% | -99.3% | -110.0% | -140.5% | -338.0% | - | 338.3% | 75.5% | 12.9% | 50.3% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | -142.7% | -119.7% | -29.0% | -96.3% | - | -126.4% | -1,613.1% | -149.5% | -95.5% | -110.8% | -107.2% | -201.1% | - | 1,748.9% | 82.4% | 10.1% | 54.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Aberdeen Group plc | 12.73% | 400.00K | $6.98M |
| 2 | Siren, L.L.C. | 12.73% | 400.00K | $6.98M |
| 3 | EcoR1 Capital, LLC | 12.73% | 400.00K | $6.98M |
| 4 | Nantahala Capital Management, LLC | 12.73% | 400.00K | $6.98M |
| 5 | Samsara BioCapital, LLC | 12.73% | 400.00K | $6.98M |
| 6 | Stonepine Capital Management, LLC | 12.63% | 397.16K | $6.93M |
| 7 | Vanguard Capital Management LLC | 2.50% | 78.68K | $1.37M |
| 8 | Vanguard Fiduciary Trust Co | 0.34% | 10.60K | $185.00K |
| 9 | Seven Grand Managers, LLC | 0.32% | 10.00K | $174.50K |
| 10 | Morgan Stanley | 0.05% | 1.54K | $26.94K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELOX
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE4xdmVfMElDNzYtV0F1NmFnWlJfbzRMV29PVTloTldPRVRrcTdqZ1FUeGdTYXZGQldET0d0OTFSeGtPNGpvbjFqcXRTU1hTRnN5?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNWWJnM3ZfcHhwdDdkSmJyZUt3RnBiVnE4SmI0c0hDTURXMHJtODZ4WGI2R003RlVLSHZtMmgxOF8zR18yWllzSzcyN2w3Tzc5RTdPTkVINGJLREtWb1JmdXh2RWNrb2hiYUNtSkZsTHB1WnNlaUpSMWl4UVJ3YkppbzVURzZoc0s1TG84en…
Eloxx Pharma Raises $66M for Nasdaq Uplisting - AllSci
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxORDlEMzlUT3FuQnI1WWhSSlAwb0loZ1FPRUdoQS1GUnp0UlY5TnFEMjV2NWNsLVBNbjdXSHpnZXlYdnIxTkZOcU1rYzh4aDk5OU9qUFRBYWM0WldEeXNZUGF5WDh1Y2xsbVdhb3JQTDFRMTY4ZE44VEczcXhEOEFSNXVzMF9sUTJIekFzOX…
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) Share Price, ELOX Stock News, ELOX Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1kLWd5aVFXRTI3OWdvVkVIQWNHbWwyenVVZkZFUkVyamk3NElfWjFZUVJYbW10aDRoejJJSFNBQm00S3JoOXlyQjVBWWpObDVReDFsMExR?oc=5" target="_blank">Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) Share Pr…
Certain Stock Options of Eloxx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2026. - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxPUGI0MWJkYkJrb1lKRGJEclN6dlJqaEJFYmxRaDczdGpwemZaVnBnR0dseGl5ZTBNb2s3d0dwa2s5aTBGYUh3Tk9hYmNvZnJ3MG9EOVpCZGRES1BVekdnaWFjQ0ZGOEctVjctUklRTXNGTGNvNmhMVXBJaUt5Q0pqZzI0YW41UmlLLU1VQ0…
Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQdnE4RXptSnlqOW1mSG1zVUtSTTVNZk1STnNqbExpa2dRak5HVV9nekxibEczSHMyUVpZZVUyT2IxaWNYU19GaG50bkRnMXl3NUp3QnJEeDVsSkR3bWtieHZGeVJaTDh0WHE0ZThmam5kaHIyZ2RLODViZVk2U1RhU1FJZmdOeDctREYwMW…
ELOX — Frequently Asked Questions
What is the current share price of Eloxx Pharmaceuticals, Inc. (ELOX)?
As of 2026-09-19 21:16 PDT, Eloxx Pharmaceuticals, Inc. (ELOX) trades at $16.17 on NasdaqCM. Its 52-week range is $10.95 to $20.98.
What is the market capitalisation of ELOX?
Eloxx Pharmaceuticals, Inc. (ELOX) has a market capitalisation of $55.57M on NasdaqCM.
What is the P/E ratio of ELOX?
ELOX trades at a trailing price-to-earnings (P/E) ratio of 4.59. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.44.
What is the return on equity (ROE) of ELOX?
ELOX has a return on equity (ROE) of 50.35%. Its return on capital employed (ROCE) is 54.07%.
Is ELOX a good stock to buy?
This page provides a data-driven analysis of Eloxx Pharmaceuticals, Inc. (ELOX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.